US · PEN
Penumbra, Inc.
- Sector
- Healthcare · Medical - Devices
- Headquarters
- Alameda, CA 94502
- Website
- penumbrainc.com
Price · as of 2025-12-31
$325.33
Market cap 13.51B
Valuation summary
Four models, one snapshot. Upside is target ÷ current − 1.
| Valuation method | Value, $ | Upside, % |
|---|---|---|
| Artificial Intelligence(AI) | $218.96 | -32.7% |
| Intrinsic Value(DCF) | $249.38 | -23.35% |
| Graham-Dodd Method(GD) | $55.23 | -83.02% |
| Graham Formula(GF) | $113.11 | -65.23% |
Valuation history
Annual price (USD per share) overlaid with each model's fair value. Y-axis is log scale.
| Year | Price | AI | DCF | Graham-Dodd | Graham Formula |
|---|---|---|---|---|---|
| 2011 | |||||
| 2012 | |||||
| 2013 | |||||
| 2014 | $0.00 | $4.35 | |||
| 2015 | $42.73 | $70.45 | $2,587.71 | $20.37 | $10.70 |
| 2016 | $80.25 | $101.03 | $795.81 | $11.18 | $23.21 |
| 2017 | $118.65 | $177.13 | $366.93 | $12.60 | $4.77 |
| 2018 | $139.00 | $87.53 | $416.07 | $12.40 | $7.33 |
| 2019 | $180.88 | $138.46 | $239.18 | $20.73 | $42.02 |
| 2020 | $278.74 | $223.72 | $0.00 | $15.51 | $0.00 |
| 2021 | $192.20 | $157.51 | $70.81 | $22.14 | $5.76 |
| 2022 | $246.09 | $397.17 | $12.19 | $21.74 | $0.00 |
| 2023 | $244.54 | $334.37 | $130.28 | $38.21 | $75.90 |
| 2024 | $274.79 | $162.19 | $47.16 | $27.31 | $7.39 |
| 2025 | $342.30 | $218.96 | $133.96 | $55.23 | $113.11 |
AI valuation
Our deep-learning model estimates Penumbra, Inc.'s (PEN) per-share fair value from quarterly fundamentals, sector trend, and historical valuation patterns.
- AI fair value
- $218.96
- Current price
- $325.33
- AI upside
- -32.7%
Methodology and confidence bands appear in the dedicated valuation theory section. The AI score is an estimate, not a recommendation.
Intrinsic value (DCF)
Open DCF calculatorThree textbook valuation models, recomputed daily from the latest financial statements. The DCF uses our Chepakovich model. Graham-Dodd and Graham Formula are conservative reference points.
DCF
$249.38
-23.35% upside
Graham-Dodd
$55.23
-83.02% upside
Graham Formula
$113.11
-65.23% upside
Peer comparison
Same-industry comparables, ranked by market cap.
| Basic Info | Model Valuation | Core Valuation | Profitability | Leverage & Liquidity | Growth | Cash Flow | Dividends | Enterprise Value | Risk | ||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ticker | Company Name | Price | Market Cap | AI Upside | DCF Upside | GD Upside | GF Upside | P/E | P/B | P/S | EV/EBITDA | PEG | P/TBV | Gross Margin | Operating Margin | Net Margin | ROE | ROIC | ROA | Debt/Equity | Interest Coverage | Current Ratio | Quick Ratio | Net Debt/EBITDA | EPS Growth | Sales Growth | FCF Growth | FCF Yield | Op Cash Flow Ratio | Cash ROIC | Dividend Yield | Dividend Payout | Shareholder Yield | EV/EBIT | EV/FCF | EV/Sales | Altman Z-Score |
| PEN | Penumbra, Inc. | $325.33 | 13.51B | -33% | -23% | -83% | -65% | 74.97 | 9.33 | 9.49 | 59.99 | 6.49 | 10.62 | 67.14% | 13.48% | 12.66% | 13.78% | 13.14% | 10.58% | 0.15 | — | 6.64 | 2.06 | 0.15 | 115556.00% | 1750.00% | 1876.00% | 1.31% | 1.30 | 14.03% | 0.00% | 0.00% | 0.00% | 70.57 | 76.34 | 9.51 | 22.01 |
| ALGN | Align Technology, Inc. | $190.10 | 13.64B | +1% | -52% | -59% | -74% | 33.42 | 3.39 | 3.40 | 15.94 | 6259.75 | 3.96 | 68.33% | 15.27% | 10.17% | 10.39% | 14.49% | 6.59% | 0.02 | — | 1.36 | 1.14 | -1.27 | 53.00% | 90.00% | -473.00% | 4.33% | 0.31 | 19.89% | 0.00% | 0.00% | 0.64% | 20.61 | 21.41 | 3.15 | 4.87 |
| BAX | Baxter International Inc. | $20.37 | 10.48B | +17% | -61% | — | — | -10.55 | 1.65 | 0.90 | 23.68 | -27.93 | -3.19 | 30.05% | -2.74% | -8.51% | -14.62% | -1.88% | -4.18% | 1.63 | -1.06 | 2.31 | 1.31 | 10.49 | 3780.00% | 572.00% | -4222.00% | 3.20% | 0.28 | 1.97% | 3.45% | -36.40% | 39.56% | -58.89 | 56.15 | 1.61 | 2.13 |
| BIO | Bio-Rad Laboratories, Inc… | $278.44 | 7.52B | +7% | -54% | +41% | -13% | 10.03 | 1.02 | 2.95 | 15.99 | — | 1.14 | 52.01% | 10.47% | 29.42% | 10.84% | 3.01% | 7.62% | 0.21 | 5.52 | 5.62 | 3.90 | 2.10 | -14264.00% | 65.00% | 4072.00% | 4.91% | 1.03 | 5.46% | 0.00% | 0.00% | 3.88% | 28.14 | 20.32 | 2.95 | 3.15 |
| CRL | Charles River Laboratorie… | $178.49 | 8.78B | -31% | -60% | — | — | -62.27 | 2.80 | 2.20 | 12.85 | — | 146.61 | 30.52% | 12.65% | -3.59% | -4.29% | 8.46% | -1.94% | 0.97 | 4.74 | 1.29 | 0.82 | 3.13 | -155500.00% | -85.00% | 337.00% | 5.86% | 0.66 | 8.64% | 0.00% | 0.00% | 4.07% | 23.05 | 22.57 | 2.91 | 2.48 |
| DVA | DaVita Inc. | $156.30 | 10.45B | -3% | -61% | — | -21% | 12.29 | -20.36 | 0.97 | 10.42 | — | -1.57 | 27.00% | 14.74% | 5.47% | -407.09% | 12.61% | 6.21% | -23.12 | 3.66 | 1.29 | 1.19 | 5.41 | -1137.00% | 646.00% | -1063.00% | 9.89% | 0.60 | 10.50% | 0.00% | 0.00% | 13.52% | 13.69 | 21.00 | 2.02 | 1.68 |
| GMED | Globus Medical, Inc. | $95.46 | 12.89B | +11% | +76% | -55% | 0% | 23.57 | 2.77 | 4.31 | 16.77 | 5.58 | 5.30 | 67.41% | 16.33% | 18.30% | 12.29% | 10.63% | 10.19% | 0.03 | — | 4.26 | 2.48 | -0.56 | 42267.00% | 1665.00% | 4530.00% | 4.64% | 1.51 | 14.79% | 0.00% | 0.00% | 3.63% | 25.51 | 20.79 | 4.16 | 12.01 |
| HIMS | Hims & Hers Health, Inc. | $14.52 | 3.19B | +579% | +6,822% | -72% | +154% | 28.88 | 6.85 | 1.58 | 24.62 | — | 55.76 | 59.31% | 5.18% | 5.47% | 25.23% | 17.20% | 8.97% | 2.34 | — | 1.90 | 1.51 | 5.80 | -377.00% | 5900.00% | -6271.00% | 1.99% | 0.74 | 10.45% | 0.00% | 0.00% | 2.43% | 36.11 | 59.40 | 1.87 | 2.78 |
| HQY | HealthEquity, Inc. | $76.49 | 6.61B | -8% | -56% | -86% | -60% | 73.84 | 3.38 | 5.95 | 23.56 | 105.02 | -9.68 | 57.73% | 19.18% | 8.06% | 4.66% | 6.98% | 2.92% | 0.52 | 3.79 | 3.06 | 2.65 | 2.41 | 7031.00% | 2003.00% | 7167.00% | 4.73% | 2.17 | 12.30% | 0.00% | 0.00% | 1.70% | 34.57 | 23.55 | 6.63 | 3.98 |
| HSIC | Henry Schein, Inc. | $82.39 | 9.99B | +2% | -60% | -90% | -52% | 24.70 | 3.03 | 0.75 | 13.28 | 342.43 | -4.95 | 29.14% | 5.75% | 3.02% | 11.99% | 9.02% | 3.71% | 1.14 | 5.05 | 1.38 | 0.56 | 3.51 | 721.00% | 403.00% | -1331.00% | 5.83% | 0.22 | 8.87% | 0.00% | 0.00% | 8.65% | 17.63 | 23.32 | 1.01 | 2.86 |
About Penumbra, Inc.
Penumbra, Inc. designs, develops, manufactures, and markets medical devices in the United States and internationally. The company offers aspiration based thrombectomy systems and accessory devices, including revascularization device for mechanical thrombectomy, such as Penumbra System under the Penumbra RED, JET, ACE, 3D Revascularization Device, and Penumbra ENGINE brands, as well as components and accessories; neurovascular embolization coiling systems to treat patients with various sizes of aneurysms and other neurovascular lesions under the Penumbra Coil 400, POD400, PAC400, and Penumbra SMART Coil brand names; and neurovascular access systems designed to provide intracranial access for use in a range of neurovascular therapies under the Neuron, Neuron MAX, Select, BENCHMARK, BMX96, DDC, and PX SLIM brands. It also provides neurosurgical aspiration tools for the removal of tissue and fluids under the Artemis Neuro Evacuation Device brand; aspiration-based thrombectomy systems for vascular applications under the Indigo System brand; and detachable embolic coil systems for peripheral embolization under the Ruby Coil and Ruby LP brand names. In addition, the company offers microcatheter for the delivery of detachable coils and occlusion devices under the LANTERN brand; and detachable, microcatheter-deliverable occlusion devices designed primarily to occlude peripheral vessels under the POD (Penumbra Occlusion Device) brand, as well as immersive computer-based technologies and immersive therapeutics to promote health, motor function, and cognition under the Real Immersive System brand; and a complementary device for use with Ruby Coil and POD for vessel occlusion under the Packing Coil and Packing Coil LP brands. The company sells its products through direct sales organizations and distributors. Penumbra, Inc. was incorporated in 2004 and is headquartered in Alameda, California.
- CEO
- Adam Elsesser
- Employees
- 4.5K
- Beta
- 0.81
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Upside computed as ($249.38 ÷ $325.33) − 1 = -23.35% (DCF, example).